Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus
Journal
International Journal of Antimicrobial Agents
Journal Volume
40
Journal Issue
2
Pages
103-107
Date Issued
2012
Author(s)
Wang J.-L.
Tang H.-J.
Hsieh P.-H.
Chiu F.-Y.
Chen Y.-H.
Chang M.-C.
Huang C.-T.
Liu C.-P.
Lau Y.-J.
Hwang K.-P.
Ko W.-C.
Liu C.-Y.
Liu C.-L.
Abstract
There is a lack of surveillance data on resistance to fusidic acid (FA) in Asia, and no reviews of FA usage for the treatment of orthopaedic infections have been conducted since the year 2000. In this study, we present a systemic literature review of FA resistance in Asia and the clinical use of FA for the treatment of bone and joint infections (BJIs). The in vitro activity of FA against meticillin-resistant Staphylococcus aureus (MRSA) isolates remains good, with low (<10%) resistance rates in most Asian countries. FA in Asia appears to be a better oral anti-MRSA agent than trimethoprim/sulfamethoxazole and clindamycin. More than 80 cases of FA use for BJI have been reported since 2000 and the recurrence or failure rate is <10%. There is much evidence supporting the use of FA in combination with other antibiotics (e.g. rifampicin) as an oral treatment following intravenous glycopeptide treatment for BJIs. ? 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
SDGs
Other Subjects
chloramphenicol; ciprofloxacin; clindamycin; cotrimoxazole; doxycycline; fosfomycin; fusidate sodium; fusidic acid; glycopeptide; linezolid; minocycline; pristinamycin; rifampicin; teicoplanin; vancomycin; antibacterial activity; antibiotic resistance; Asia; bacterial arthritis; bone and joint infections; drug excretion; drug metabolism; drug potentiation; drug treatment failure; endocarditis; Europe; human; in vitro study; infectious arthritis; loading drug dose; methicillin resistant Staphylococcus aureus; nonhuman; North America; osteomyelitis; priority journal; prosthetic joint infection; recommended drug dose; recurrent disease; review; Staphylococcus infection; systematic review; treatment outcome; vancomycin intermediate Staphylococcus aureus infection
Publisher
Elsevier B.V.
Type
short survey